Report Overview

The market for rheumatoid arthritis therapeutics has experienced remarkably strong growth during the past five years due to the introduction of the biological response modifiers (BRMs) to treatment regimens. The value of this market will reach nearly $13 billion by 2011. Sales of both Remicade and Enbrel continue to grow, while the introduction of Humira in 2003 has been a major stimulus to the market. All three of these products are now approved in both the US and Europe for rheumatoid arthritis. Added to this mix in 2006 was Rituxan and Orencia, which will both have an impact in the patient population unresponsive to other BRMs. As half-year 2006 revenues clearly indicate, revenues from the sales of all of these products will continue to trend positively in 2007.

The rheumatoid arthritis pipeline today is replete with biologic therapies designed to modify the course of the disease. There are a number of follow-on biologic products being developed, which, like Remicade, Enbrel and Humira, target TNF-a. Additionally, though, companies are investing in candidates which target other cytokines that have been implicated in disease development. Rheumatoid Arthritis Therapeutics: Market Trends and R&D Insights is arranged to provide readers with an analytically-based overview of the market for rheumatoid arthritis therapies as well as an assessment of therapeutics currently in clinical development. The report focuses primarily on the class of rheumatoid arthritis therapeutics known as the biological response modifiers (BRMs). These drugs currently account for the vast majority of sales in this therapeutic area and will continue to make a strong impact in the coming years.

Key features of this report: